CRISPR筛选CAR T细胞与胶质瘤干细胞揭示细胞治疗关键依赖
该研究在CAR T细胞和患者来源的胶质母细胞瘤干细胞(GSC)中开展全基因组CRISPR筛选,以解析CAR介导杀伤的分子决定因素。CAR T细胞筛选发现TLE4和IKZF2等效应功能依赖基因,敲除后增强抗肿瘤效力;GSC反向筛选发现RELA和NPLOC4等对CAR杀伤易感性必需基因,敲除后改变肿瘤免疫信号并提高CAR治疗反应性。
要点
- CAR T细胞中敲除TLE4或IKZF2可增强抗肿瘤效力并抑制耗竭。
- GSC中敲除RELA或NPLOC4可提高对CAR杀伤的易感性。
- 双向CRISPR筛选为增强实体瘤CAR疗效提供分子靶点策略。
核心结论
- 在CAR T细胞和胶质母细胞瘤干细胞中开展双向全基因组CRISPR筛选,发现增强CAR对GBM杀伤效力的关键基因依赖。
研究设计与样本
- 研究在CAR T细胞和患者来源的胶质母细胞瘤干细胞(GSC)中分别进行全基因组CRISPR筛选。
主要发现
- CAR T细胞筛选鉴定出包括TLE4和IKZF2在内的效应功能依赖基因,靶向敲除这些基因增强了CAR抗肿瘤效力。
- 对编辑后CAR T细胞的bulk和单细胞RNA测序显示其转录谱呈现更优效应功能并抑制耗竭反应。
- GSC反向筛选鉴定出对CAR介导杀伤易感性必需的基因,包括RELA和NPLOC4,其敲除改变肿瘤-免疫信号并增加CAR治疗反应性。
临床怎么用
- 研究提示可通过对CAR T细胞或肿瘤细胞进行特定基因编辑(如TLE4、IKZF2、RELA、NPLOC4)以增强CAR对GBM的疗效,并可能扩展至其他实体瘤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glioblastoma (GBM) contains self-renewing GBM stem cells (GSC) potentially amenable to immunologic targeting, but chimeric antigen receptor (CAR) T-cell therapy has demonstrated limited clinical responses in GBM. Here, we interrogated molecular determinants of CAR-mediated GBM killing through whole-genome CRISPR screens in both CAR T cells and patient-derived GSCs. Screening of CAR T cells identified dependencies for effector functions, including TLE4 and IKZF2. Targeted knockout of these genes enhanced CAR antitumor efficacy. Bulk and single-cell RNA sequencing of edited CAR T cells revealed transcriptional profiles of superior effector function and inhibited exhaustion responses. Reciprocal screening of GSCs identified genes essential for susceptibility to CAR-mediated killing, including RELA and NPLOC4, the knockout of which altered tumor-immune signaling and increased responsiveness of CAR therapy. Overall, CRISPR screening of CAR T cells and GSCs discovered avenues for enhancing CAR therapeutic efficacy against GBM, with the potential to be extended to other solid tumors. SIGNIFICANCE: Reciprocal CRISPR screening identified genes in both CAR T cells and tumor cells regulating the potency of CAR T-cell cytotoxicity, informing molecular targeting strategies to potentiate CAR T-cell antitumor efficacy and elucidate genetic modifications of tumor cells in combination with CAR T cells to advance immuno-oncotherapy.This article is highlighted in the In This Issue feature, p. 995.
引用
- Wang D, Prager BC, Gimple RC, et al. CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies. Cancer Discov. 2020. PMID: 33328215. doi:10.1158/2159-8290.CD-20-1243
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。